SARS-CoV-2 Antibody Detection in Dried Blood Spots
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting SARS-CoV-2 antibodies in dried blood spots lack sensitivity and require complex sample collection and processing, limiting their accessibility and accuracy for large-scale population monitoring.
Innovation Solution
The development of a method using the Roche Elecsys Anti-SARS-CoV-2 S electrochemiluminescence immunoassay for detecting SARS-CoV-2 antibodies in dried blood spots, which involves self-collection, extraction, and quantitative measurement, with a lower limit of quantitation of 0.180 U/mL and an upper range of 250 U/mL, enabling accurate monitoring of antibody levels over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used for detecting SARS-CoV-2 antibodies in dried blood spots, then sample collection is simplified, but sensitivity and measurement precision are insufficient
Solution Approach 1:
The patent modifies the electrochemiluminescence assay parameters specifically for dried blood spot samples, adjusting extraction buffers, incubation times, and detection thresholds to optimize sensitivity for DBS matrices while maintaining quantitative accuracy across the clinical range
Solution Approach 2:
The patent introduces specific extraction buffers and reagents as intermediaries to facilitate antibody recovery from the dried blood spot matrix, enabling efficient analyte release without requiring complex sample preparation procedures
2Adaptability or versatility
If quantitative detection with wide range is implemented, then monitoring capability is improved, but detection limit and sensitivity requirements increase
Solution Approach 1:
The patent employs a dynamic detection system using electrochemiluminescence technology that can adjust its sensitivity and measurement range, allowing the same assay to accurately quantify antibodies across two orders of magnitude from 0.180 U/mL to 250 U/mL by modifying signal detection parameters
Solution Approach 2:
The patent develops a universal quantitative assay that serves multiple functions: detecting both low and high antibody levels, monitoring seroconversion, tracking antibody decay, and assessing immune response magnitude, all within a single measurement platform
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a sensitive, quantitative, and accessible method for monitoring SARS-CoV-2 antibodies in dried blood spots, demonstrating high categorical agreement with venous serum results and stability during shipping, suitable for large-scale population analysis and antibody monitoring post-vaccination.
Implementation Method 1
The development of a method using the Roche Elecsys Anti-SARS-CoV-2 S electrochemiluminescence immunoassay for detecting SARS-CoV-2 antibodies in dried blood spots
Data Source
AI summary
In certain aspects, disclosed are methods and systems for detecting SARS-CoV-2 analytes in dried samples, as for example, dried blood spots. For example, disclosed are methods for measuring an antibody to SARS-CoV-2 in a dried sample that include the steps of: (a) obtaining a dried sample from a subject; (b) extracting the SARS-COV-2 antibody from the dried sample; and (c) detecting the SARS-COV-2 antibody extracted from the dried sample. In certain embodiments, the method is semi-quantitative. The method may, in certain embodiments, further comprise obtaining measurements from an individual over a period of time to follow the titer of SARS-CoV-2 antibody in the individual. For example, the titer may be followed in the individual for at least 19 weeks or longer.